Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM +1.02%25 Median PS Value is C$0.74 as of Jul. 27, 2026, which is 100% below its 10-year median of 0.95. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 277 Biotechnology companies, Eastwood Bio-Medical Canada ranks worse than 83.75% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Eastwood Bio-Medical Canada's Median PS Value or its related term are showing as below:
TSXV:EBM'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59 Med: 0.95 Max: 1.56
Current: 1.34
During the past 13 years, the highest Price to Median PS Value of Eastwood Bio-Medical Canada was 1.56. The lowest was 0.59. And the median was 0.95.
TSXV:EBM's Price-to-Median-PS-Value is ranked worse than 83.75% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs TSXV:EBM: 1.34
Eastwood Bio-Medical Canada (TSXV:EBM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Eastwood Bio-Medical Canada's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.99
/
0.74
=
1.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada Median PS Value Related Terms
Eastwood Bio-Medical Canada Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EBM vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 67.2727.
Eastwood Bio-Medical Canada's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada (TSXV:EBM) has a Median PS Value of C$0.74 as of Jul. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Eastwood Bio-Medical Canada and its competitors. This is 22% below median its historical median of 0.95. Over the past decade, Eastwood Bio-Medical Canada's Median PS Value has ranged from 0.59 to 1.56. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #232 out of 277 companies in the Biotechnology industry, placing it in the top 83.8%.
Is Eastwood Bio-Medical Canada's Median PS Value too high?
Eastwood Bio-Medical Canada's current Median PS Value of C$0.74 is 22% below median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.56. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #232 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #232 out of 277 companies for Median PS Value. This places Eastwood Bio-Medical Canada in the lower half of its industry. The industry median Median PS Value is 0.63. Historically, Eastwood Bio-Medical Canada's own Median PS Value has ranged from 0.59 to 1.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current Median PS Value is C$0.74, which is 22% below median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current Median PS Value is C$0.74, which is 22% below median its 10-year median of 0.95. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current Median PS Value is C$0.74 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
Median PS Value: C$0.74 (22% below median its 10-year median of 0.95)
GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
